Image Description (Label)
Azithromycin
Product Images NDC 61919-382
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Azithromycin (NDC 61919-382). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Module)
Image Description (Table 1)
Pharmacokinetic parameters for Tolain on Day 1 and Days (variable) are available. The parameters include Coa, T, AUCy 24, Cone, and urinary excretion. Azithromycin 250 mg tablets and capsules are bioequivalent in fasted state but capsules are no longer available commercially.*
Image Description (Table 2)
Image Description (Table 4)
Image Description (Table 5)
The text describes the pharmacokinetic parameters for coadministered drugs in the presence of the drug Azithromycin, providing information on dose and ratio (with/without) of drug coadministered. The table provides data on several drugs, including torvastatin, carbamazepine, cetirizine, diganosine, efavirenz, fluconazole, indinavir, midazolam, neffinavir, and rifabutin. For some drugs, there is a significant effect on mean Cpmy and mean AUC in the presence of Azithromycin, while for others, there is no effect.*
Image Description (Table 6)
This is a list of medical treatments and dosages, including drugs like Sildenafil, Theophylline, Imiglucerase, Triazolam, Trimethoprim/Sulfamethoxazole, and Zidovudine. The treatment durations range from 3 to 21 days. Rifabutin coadministration with azithromycin may result in 60 ng/mL concentration levels one-half day after the last dose. There is no information available on confidence intervals.*
Image Description (Table 7)
This is a table showing drug interactions of Azithromycin when coadministered with other drugs, stating the dose of Azithromycin and the coadministered drug. Pharmacokinetic parameters with and without the coadministered drug are also shown, as well as a ratio of these parameters (with/without the coadministered drug). The table includes drugs such as Efavirenz, Fluconazole, Nelfinavir, and Rifabutin. However, there is not enough information to fully understand the data and its significance.*
Image Description (Table 8)
Table 3 shows the criteria for interpreting susceptibility tests for Azithromycin. The table includes the minimum inhibitory concentrations (mcg/mL) and zone diameters in mm for pathogens such as Haemophilus influenzae, Staphylococcus aureus, and Streptococci. It is important to note that there is insufficient information available to determine intermediate or resistant interpretive criteria. Testing for susceptibility to azithromycin should be performed in ambient air.*
Image Description (Table 9)
This is a table indicating acceptable quality control ranges for Azithromycin. The table contains minimum inhibitory disk diffusion concentrations for different strains of bacteria including Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. The strains' susceptibility to Azithromycin should be tested in ambient air. The text also abbreviates ATCC as American Type Culture Collection.*
Image Description (Table)
This text provides data on the concentration of Azithromycin, an antibiotic drug, in various tissues and fluids of adults following a dose of 500mg (two capsules of 250mg each). The table shows the concentration of the drug in different tissues such as skin, lung, sputum, tonsil, and cervix at different time intervals after the dose. The data is based on samples obtained 2 to 4 hours and 10 to 12 hours after the first dose, and 19 hours after a single dose.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
